XML 46 R35.htm IDEA: XBRL DOCUMENT

Basis of Presentation, Principles of Consolidation and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash, Cash Equivalents and Restricted Cash [Abstract]
Cash and cash equivalents	$ 264,608		$ 264,608		$ 297,098
Restricted cash	1,334		1,334		1,568
Total	265,942	$ 164,728	265,942	$ 164,728	$ 298,666	$ 186,908
NYS Life Sciences Research and Development Tax Credit [Abstract]
Research and development incentive income	$ 0	$ 0	$ 500	$ 0

Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References + Details